With 0.31 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.46 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.69 whereas the lowest price it dropped to was $13.17. The 52-week range on PLRX shows that it touched its highest point at $19.62 and its lowest point at $10.22 during that stretch. It currently has a 1-year price target of $40.18. Beta for the stock currently stands at 1.06.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PLRX was down-trending over the past week, with a drop of -9.46%, but this was down by -3.41% over a month. Three-month performance surged to 12.05% while six-month performance rose 12.71%. The stock lost -14.30% in the past year, while it has lost -26.56% so far this year. A look at the trailing 12-month EPS for PLRX yields -3.34 with Next year EPS estimates of -4.02. For the next quarter, that number is -0.99. This implies an EPS growth rate of -32.31% for this year and -10.46% for next year.
Float and Shares Shorts:
At present, 60.85 million PLRX shares are outstanding with a float of 53.76 million shares on hand for trading. On 2024-11-29, short shares totaled 7.24 million, which was 1189.99995 higher than short shares on 1730332800. In addition to Dr. Bernard Coulie M.B.A., M.D., Ph.D. as the firm’s President, CEO & Director, Dr. Keith Lamont Cummings M.B.A., M.D. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.1233001 of PLRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PLRX reported revenue of $0.0 and operating income of -$62014000.0. The EBITDA in the recently reported quarter was -$56354000.0 and diluted EPS was -$0.95.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PLRX since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PLRX analysts setting a high price target of 47.0 and a low target of 32.0, the average target price over the next 12 months is 40.18182. Based on these targets, PLRX could surge 253.38% to reach the target high and rise by 140.6% to reach the target low. Reaching the average price target will result in a growth of 202.12% from current levels.
Analysts have provided yearly estimates in a range of -$3.56881 being high and -$3.6984 being low. For PLRX, this leads to a yearly average estimate of -$3.63859. Based on analyst estimates, the high estimate for the next quarter is -$0.86 and the low estimate is -$1.01. The average estimate for the next quarter is thus -$0.96.
